Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 424

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 424
---
 have a material adverse effect on our financial condition and results of operations. Although we own or exclusively license fifteen (15) issued patents in the United States, we cannot be certain that the claims in our other United States pending patent applications, corresponding international patent applications and patent applications in certain foreign territories, or those of our licensors, will be considered patentable by the United States Patent and Trademark Office (the “USPTO”), courts in the United States or by the patent offices and courts in foreign countries, nor can we be certain that the claims in our issued patent will not be found invalid or unenforceable if challenged. The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our current or potential future collaborators will be successful in protecting our product or product candidates by obtaining and defending patents. These risks and uncertainties include the following:

| • |     | the USPTO and various foreign governmental patent agencies require compliance with a number of procedural,                                                                                                                                              
 documentary, fee payment and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction; |

| • |     | patent applications may not result in any patents being issued; |

| • |     | if clinical trials encounter delays, the period of time during which we could market our current or future 
 product candidates under patent protection would be reduced;                                               |

| • |     | patents may be challenged, invalidated, modified, narrowed, revoked, circumvented, found to be unenforceable, 
 found to be not infringed or otherwise may not provide any competitive advantage;                             |

| • |     | our competitors, many of whom have substantially greater resources than we do and many of whom have made 
 significant investments in competing technologies, may seek or may have already obtained                 |

- 288 -

| patents that could limit, interfere with or eliminate our ability to make, use and sell our product or potential product candidates or design around any of our owned, co-owned, or licensed patents; |

| • |     | since patent applications in the United States and most other countries are confidential for a period of time                                                                                                   
 after filing, we cannot be certain that we were the first to either (i) file any patent application related to our product; or (ii) invent any of the inventions claimed in our patents or patent applications; |

| • |     | even when laws